1-866-61-EISAI (1-866-613-4724)

Monday – Friday, 8am to 8pm ET

ALOXI® Reimbursement Information for Healthcare Professionals

Eisai is committed to supporting healthcare professionals by providing information that will help them obtain billing, coding and reimbursement information for ALOXI® (palonosetron HCI injection).

BILLING & CODING

General billing and coding information for ALOXI® (palonosetron HCI injection) and related services.

COVERAGE POLICIES

Coverage information for ALOXI® as determined by payor and setting of care.

PATIENT SUPPORT

Resources to help your patients manage their out-of-pocket costs for ALOXI®.

DOCUMENTS & RESOURCES

Resources to assist with coverage, coding, reimbursement & patient access.

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record

+ EXPAND- COLLAPSE

Indication in Pediatrics

ALOXI® injection 20mcg/kg (max 1.5mg) is indicated in patients ≥ 1 month up to 17 years of age, for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.

Indication in Adults

ALOXI® injection 0.25 mg is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Important Safety Information

Contraindications

  • ALOXI® is contraindicated in patients known to have hypersensitivity to the drug or any of its components
  • Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other 5-HT3 receptor antagonists
  • Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone, but particularly with the use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue ALOXI® and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if ALOXI® is used concomitantly with other serotonergic drugs

     

    For more information about ALOXI®, please see full Prescribing Information.
    You are encouraged to report negative side effects of prescription drugs to the FDA.
    Visit http://www.FDA.gov/medwatch or call 1-800-FDA-1088.

  • This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc. 

    ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.
    Distributed and marketed by Eisai Inc and Helsinn Therapeutics (U.S.), Inc.
    CORP-US0106g